About us

Almirall is a leading skin-health focused global pharmaceutical company based in Barcelona that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations. Our efforts are focused on fighting skin health diseases and helping people feel their best. We support healthcare professionals in continuous improvement, bringing our innovative solutions to where they are needed most.

This is Almirall's legacy for future generations, it is our contribution to society

See video Purpose

At a glance

Last updated: May / 2024

Global dimension

2027Total number of employees

14Affiliates within EU & US

+100Country presence

985.7Net Sales (€ MM)

12.6%Investment of Net Sales in R&D

40Nationalities

Some of our major milestones

1944Foundation of Laboratory Almirall, S.A

1960Almirall starts its research and development activities

1984Launch of the antacid almagate in Spain

1990Launch of the antihistame ebastine in Spain and concession of licences on an international scale

1997Creation of Laboratorios Almirall Prodesfarma S.A., as a result of the merger between the Grupo Pharmaceutics Almirall, S.A. and the Grupo Prodesfarma

2007Almirall acquires Hermal, a European prescription dermatology business of Reckitt Benckiser

2012The European Medicines Agency (EMA) approves the commercialisation of Almirall's aclidinium for the treatment of chronic obstructive pulmonary disease (COPD) in Europe, where it will be marketed as Eklira® Genuair® and Bretaris® Genuair®

2013Almirall reaches an agreement to acquire Aqua Pharmaceuticals, a US- based specialty dermatology company

2014Almirall has transferred to AstraZeneca the rights of its respiratory franchise, including the development and commercialization of Almirall's existing proprietary respiratory business, including rights to revenues from Almirall's partnerships, as well as its pipeline of investigational novel therapies

2015Acquisition of Poli Group, a pharmaceutical company which specializes in Dermatology and is the world leader in nail diseases and treating disorders such as onychomycosis, nail psoriasis and nail dystrophy, skin mycosis, rosacea and acne, among others

2016Almirall and Sun Pharmaceutical Industries Ltd. sign a licensing agreement for the development and commercialization of tildrakizumab within Europe, a novel biologic treatment for patients with moderate-to-severe plaque psoriasis

2018In August, Almirall entered an agreement to acquire 5 products of Allergan’s U.S. medical dermatology portfolio for acne and dermatoses. It comprises a balanced portfolio of mature and growth brands. Aczone® (dapsone), Tazorac® (tazarotene), Azelex® (azelaic acid) and Cordran® Tape (fludroxycortide), as well as Seysara® (sarecycline)